Top Stories
Aspen is moving a Parkinson's disease cell therapy into Phase III testing, while Bambusa is advancing a portfolio of bispecific antibodies for inflammatory conditions.
The oral ileal bile acid transporter inhibitor significantly improved cholestatic pruritus compared with placebo.
BMS gained the alpha-emitting therapy RYZ101 through the $4.1-billion purchase of RayzeBio.
Thomas Appio, who is CEO of Bausch Health, will lead the firm on an interim basis.
The treatment's 17.05-metre improvement on the six-minute walk test distance over placebo in adolescents and adults was deemed statistically non–significant.
Conference News
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCMSOUTH SAN FRANCISCO, Calif., Oct. 12, 2026...
–ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in insufficient levels of OPA1 protein, leading to progressive and irreversible...
Phase 1b study in atopic dermatitis demonstrated a statistically significant mean reduction of 2.1 years in measured skin epigenetic age after four weeks of treatment with RLS-1496 (p=0.032), with red...
ATHENS, Ga. and SAN JOSE, Calif., Oct. 12, 2026 /PRNewswire/ -- Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines tha...
New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposureFindings build on first positive resul...
